Mutares Stock Reclaims Key Threshold as Management Scrambles to Restore Covenant Compliance
20.06.2026 - 13:33:47 | boerse-global.de
A sharp rally in Mutares shares has put the SDAX-listed private equity firm back in focus, even as management races to repair a breached debt covenant by the end of next June. The stock surged to €29.40 on Friday, breaking decisively above its 200-day moving average at €28.96 and posting a single-day gain of 3.7%. That move has lifted the equity roughly 9% over the past month and marked a clear departure from the lows of €23.30 hit in April.
The catalyst was twofold. First came the confirmation of a fresh acquisition: Mutares is buying Synthomer, a Czech specialist in acrylate solutions with annual revenues of around €110 million. The deal, expected to close by the end of the third quarter of 2026, significantly expands the group’s chemicals and materials segment. Chief Investment Officer Johannes Laumann has flagged the unit as a future exit candidate, a signal that has resonated with investors looking for the next monetisation event.
But the wider picture is more complex. Mutares missed its target ratio of net debt to equity during 2025, squeezed by a slowdown in disposals and a rise in leasing liabilities. Bondholders granted a reprieve, pushing the compliance deadline to the end of June 2026. To meet that test, the group has piled on two more acquisitions beyond Synthomer: the gas business of Finland’s Wärtsilä and a division of petrochemicals giant SABIC. Both were struck in early June and are expected to generate substantial book profits, helping to nudge the leverage metric back into the green.
Deleveraging is also proceeding apace. Mutares has committed to buying back at least €25 million worth of its own bonds every quarter, aiming to bring total outstanding debt down to no more than €300 million by year-end. That effort will be bolstered by cash inflows from exits. The sale of NEM Energy to Hyundai Heavy Industries is on track for completion in the third quarter of 2026, while a potential IPO or sale of Portuguese subsidiary Efacec — which could contribute up to €50 million in operating earnings this year — is being explored with the help of JPMorgan.
Should investors sell immediately? Or is it worth buying Mutares?
Not all analysts have held their nerve. Warburg Research recently trimmed its price target for Mutares to €41, though it maintained a buy rating. The stock is now trading just below the psychologically important €30 mark; a sustained break above that level would put last year’s all-time high back in play, according to the same team. On the technical side, the RSI currently sits at 63.5 — comfortably below the overbought threshold, suggesting room for further upside.
Yet a note of caution comes from Citadel strategist Scott Rubner, who has warned of potential technical headwinds through the end of the current quarter. That could inject some short-term volatility into a stock that has already climbed sharply from its April trough.
On the corporate calendar, the annual general meeting is set for July 3. Management has proposed a base dividend of €2.00 per share, with an additional bonus possible should further disposals fill the coffers. The underlying assumption is a net profit of €165 million for the full year. If the covenant fix is achieved by next June, Mutares plans to funnel the freed-up firepower into expansion in the United States — a market that has long been on the group’s radar.
Mutares at a turning point? This analysis reveals what investors need to know now.
For now, the interplay between deal-making, debt reduction, and a resurgent share price is keeping the story alive. The next few quarters will tell whether the balance sheet repair comes through on schedule.
Ad
Mutares Stock: New Analysis - 20 June
Fresh Mutares information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
